Developer docs
API playgroundTry for free, no card

Search company profiles

Medcognetics

Full company profile

uuid0003u1x

Namestring
Medcognetics
Legal namestring
MedCognetics, Inc.
Company typeenum
Private
Founded yearint
2020
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDallas, United States
HQ citystring
Dallas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical imaging AI, breast cancer detection, radiology triage software, lung disease screening, FDA-cleared diagnostics
Industry2 codes
PRIMARYHLACALAC
Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAHABAF
Mammography & Breast Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Imaging AI Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1AI Software Licenses/Subscriptions
TypeSubscription Recurring
Description

MedCognetics generates revenue through licensing its FDA-cleared AI software (CogNet AI-MT, CogNet AI-MT+) to healthcare institutions including hospitals and imaging centers. The company offers cloud-based, on-premises, and embedded deployment options, suggesting subscription or license-based pricing models for its AI products.

medcognetics.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1Enterprise licensing with flexible deployment options
ModelSubscriptionBilling cadenceAnnual
Notes

No public pricing listed. Sales conducted through direct enterprise outreach and demo requests.

medcognetics.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1CogNet Mammo
Description

AI suite for breast cancer screening and women's health outcomes, including triage, detection, density assessment, patient risk scoring, and breast arterial calcification analysis.

medcognetics.com
+4 more records
Core offering1 text field

MedCognetics develops and licenses AI-powered medical imaging software for breast cancer and lung disease detection. Its core CogNet platform provides FDA-cleared computer-aided triage, detection, density classification, patient risk scoring, and breast arterial calcification analysis for mammography, as well as chest X-ray and low-dose CT analysis for lung screening. The software is offered via cloud, on-premises, embedded, and web portal deployment to hospitals, imaging centers, and global health programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Reduces diagnostic review time and enables radiologists to prioritize suspicious mammograms
+1 more record
Product overview1 text field

Medcognetics offers a unified AI platform with multiple product lines. The core CogNet Mammo suite (built on US patents 11,948,297 B1 and 12,243,232 B1) provides breast cancer screening AI including triage (CogNet AI-MT/AI-MT+), detection, density assessment, patient risk scoring, and breast arterial calcification analysis. CogNet Lung extends AI capabilities to chest X-ray and low-dose CT for lung disease detection. The platform supports Flexible Deployment options (cloud, on-premises, embedded, web portal) and includes Proprietary Tools for AI development. CogNet AI-MT received FDA 510(k) clearance in December 2022, with CogNet AI-MT+ receiving FDA clearance in February 2026 for DBT triage.

Product and service6 records
1CogNet Mammo
CategoryAI breast imaging software suite
Description

Comprehensive AI suite for breast cancer screening and women's health, including triage, detection, density classification, patient risk scoring, and breast arterial calcification analysis. Built on two foundational U.S. patents for unbiased mammogram analysis. Targets hospitals, imaging centers, and global health programs.

2CogNet AI-MT+
CategoryAI breast imaging triage software
Description

FDA 510(k) cleared AI-enabled radiological computer-aided triage and notification software for breast imaging. Flags suspicious 3D mammography (DBT) exams for prioritized radiologist review, helping manage increasing imaging volumes.

3CogNet AI-MT
CategoryAI breast imaging triage software
Description

FDA-cleared AI platform for triage of mammogram images in the cloud. Analyzes screening mammograms and flags exams suggestive of suspicious findings for worklist prioritization and workflow optimization.

4CogNet Lung
CategoryAI lung imaging software suite
Description

Suite of AI products for lung cancer screening and disease detection, including chest X-ray and low-dose CT analysis for abnormality detection, nodule identification, and lung disease screening.

5Embedded AI
CategoryEdge AI medical imaging hardware/software system
Description

Embedded AI image processing and cancer detection system combining medical-grade edge AI hardware with CogNet AI-MT software, enabling on-premises deployment with real-time results, enhanced image quality (denoising, microcalcification enhancement, motion suppression), and workflow optimization directly in the imaging device.

6Proprietary Tools
CategoryAI development platform / tools
Description

End-to-end AI development platform including synthetic data generation, generative AI-powered data curation, an evaluation framework for subgroup-specific performance testing, data annotation tools, and foundation models for breast and lung imaging. Sold as a standalone offering for AI development and validation.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-05-09
Description

Partnership with Pune-based nonprofit HWRF to deploy AI-enabled mobile mammography units across India. The initiative brings screening directly to underserved and remote rural communities, using edge-based deployment for real-time image processing in areas with limited connectivity.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-23
Description

Collaboration to develop integrated AI workflow and security solutions for breast cancer screening and diagnosis. The partnership aims to improve clinical efficiency, data security, and patient outcomes while supporting FDA standards for trustworthy AI in healthcare.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partnership with UT Dallas, where the company was co-founded. Lakshman Tamil serves as Co-founder and Professor at UT Dallas. The partnership supports ongoing AI research and development for medical imaging.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with UTSW for AI development and validation in medical imaging. Part of Dallas-based healthcare ecosystem.

5AWS Partner Network
Strategic tierCoreTypeTechnology or Integration
Description

MedCognetics is a member of the AWS Partner Network, enabling cloud-based deployment of FDA-cleared AI solutions through secure, HIPAA-compliant AWS infrastructure.

medcognetics.com
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Clinical deployment partnership with NM Medical in Mumbai, India. Dr. Shilpa Lad serves as radiologist advisor. Has screened thousands of patients across diverse ethnic demographics.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Partnership with AKARUI Solutions to deploy MedCognetics' AI imaging platform for expanding breast cancer screening access in rural India.

8Four Nigerian University Hospitals
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Deployment of unbiased AI platform in four Nigerian university hospitals, screening thousands of patients across diverse ethnic demographics as part of the company's global health initiative.

medcognetics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Broad radiology AI platform with FDA-cleared algorithms across multiple modalities including chest CT, sold to large hospital systems—an incumbent MedCognetics competes against when extending into lung.

TypeDirect peer
Description

Provides ClearRead CT and ClearRead XR AI tools for chest imaging, directly comparable to MedCognetics' CogNet Lung suite for lung cancer screening and chest X-ray analysis.

TypeDirect peer
Description

Developer of cmTriage and cmAngio AI for mammography workflow and cancer detection, focused on the same hospital and imaging-center customer segment.

TypeDirect peer
Description

French AI vendor with MammoScreen 2.0 for mammography triage and detection, an FDA-cleared competitor to MedCognetics' CogNet AI-MT+ in the U.S. market.

TypeDirect peer
Description

Korean AI company with INSIGHT MMG and INSIGHT DBT for mammography triage and detection, plus INSIGHT CXR for chest X-ray—directly overlapping MedCognetics' breast and lung AI roadmap and global commercial footprint.

TypeDirect peer
Description

Mammography AI vendor behind ProFound AI for DBT and 2D mammography, with FDA-cleared triage, detection, and risk products serving U.S. hospitals and imaging centers in the same customer base.

TypeBroad incumbent
Description

Mammography equipment OEM (Selenia Dimensions / 3Dimensions) that bundles its own Genius AI for DBT. Competes both at the device level and the AI-software layer MedCognetics targets.

TypeDirect peer
Description

Provides AI-powered breast imaging analytics including density assessment and risk scoring (Volpara Scorecard), sold to the same hospital and imaging-center customers MedCognetics targets.

TypeDirect peer
Description

Developer of Transpara, an FDA-cleared AI decision-support tool for mammography (2D and DBT) used in U.S. and European screening programs—directly comparable to CogNet AI-MT/AI-MT+.

TypeDirect peer
Description

RadNet-owned AI subsidiary offering Saige-Dx for mammography decision support and a broader radiology AI portfolio, with deep U.S. imaging-center distribution.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medcognetics

Medical Imaging AI Softwaremedcognetics.com

Medcognetics firmographics

Firmographics
Name
Medcognetics
Legal name
MedCognetics, Inc.
Website
https://medcognetics.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Medcognetics industry classification

Industry
Product category
Medical Imaging AI Software
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACALAC
Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAHABAF
Mammography & Breast Imaging Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

  • Medical imaging AI
  • Breast cancer detection
  • Radiology triage software
  • Lung disease screening
  • FDA-cleared diagnostics

Where Medcognetics is headquartered

Location

Headquarters

HQ city
Dallas
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Medcognetics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. AI Software Licenses/Subscriptions: MedCognetics generates revenue through licensing its FDA-cleared AI software (CogNet AI-MT, CogNet AI-MT+) to healthcare institutions including hospitals and imaging centers. The company offers cloud-based, on-premises, and embedded deployment options, suggesting subscription or license-based pricing models for its AI products.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise licensing with flexible deployment options

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Medcognetics product offering

Product offering

Core offering

MedCognetics develops and licenses AI-powered medical imaging software for breast cancer and lung disease detection. Its core CogNet platform provides FDA-cleared computer-aided triage, detection, density classification, patient risk scoring, and breast arterial calcification analysis for mammography, as well as chest X-ray and low-dose CT analysis for lung screening. The software is offered via cloud, on-premises, embedded, and web portal deployment to hospitals, imaging centers, and global health programs.

Product overview

Medcognetics offers a unified AI platform with multiple product lines. The core CogNet Mammo suite (built on US patents 11,948,297 B1 and 12,243,232 B1) provides breast cancer screening AI including triage (CogNet AI-MT/AI-MT+), detection, density assessment, patient risk scoring, and breast arterial calcification analysis. CogNet Lung extends AI capabilities to chest X-ray and low-dose CT for lung disease detection. The platform supports Flexible Deployment options (cloud, on-premises, embedded, web portal) and includes Proprietary Tools for AI development. CogNet AI-MT received FDA 510(k) clearance in December 2022, with CogNet AI-MT+ receiving FDA clearance in February 2026 for DBT triage.

Differentiator

Problem solved

Functional benefit

Brands

  • CogNet Mammo: AI suite for breast cancer screening and women's health outcomes, including triage, detection, density assessment, patient risk scoring, and breast arterial calcification analysis.
  • CogNet Lung
  • CogNet AI-MT
  • CogNet AI-MT+
  • Proprietary Tools

Products and services

  • CogNet Mammo Comprehensive AI suite for breast cancer screening and women's health, including triage, detection, density classification, patient risk scoring, and breast arterial calcification analysis. Built on two foundational U.S. patents for unbiased mammogram analysis. Targets hospitals, imaging centers, and global health programs.
  • CogNet AI-MT+ FDA 510(k) cleared AI-enabled radiological computer-aided triage and notification software for breast imaging. Flags suspicious 3D mammography (DBT) exams for prioritized radiologist review, helping manage increasing imaging volumes.
  • CogNet AI-MT FDA-cleared AI platform for triage of mammogram images in the cloud. Analyzes screening mammograms and flags exams suggestive of suspicious findings for worklist prioritization and workflow optimization.
  • CogNet Lung Suite of AI products for lung cancer screening and disease detection, including chest X-ray and low-dose CT analysis for abnormality detection, nodule identification, and lung disease screening.
  • Embedded AI Embedded AI image processing and cancer detection system combining medical-grade edge AI hardware with CogNet AI-MT software, enabling on-premises deployment with real-time results, enhanced image quality (denoising, microcalcification enhancement, motion suppression), and workflow optimization directly in the imaging device.
  • Proprietary Tools End-to-end AI development platform including synthetic data generation, generative AI-powered data curation, an evaluation framework for subgroup-specific performance testing, data annotation tools, and foundation models for breast and lung imaging. Sold as a standalone offering for AI development and validation.

Quantifiable outcome

  • Reduces diagnostic review time and enables radiologists to prioritize suspicious mammograms
  • +1 more outcomes

Companies that use Medcognetics

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Medcognetics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature10 records

Medcognetics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered flagship and core.

  • Health Within Reach Foundation (HWRF)flagshipStrategic or Co-development Partner · 9 May 2026Partnership with Pune-based nonprofit HWRF to deploy AI-enabled mobile mammography units across India. The initiative brings screening directly to underserved and remote rural communities, using edge-based deployment for real-time image processing in areas with limited connectivity.
  • Laurel Bridge SoftwarecoreTechnology or Integration · 23 October 2025Collaboration to develop integrated AI workflow and security solutions for breast cancer screening and diagnosis. The partnership aims to improve clinical efficiency, data security, and patient outcomes while supporting FDA standards for trustworthy AI in healthcare.
  • University of Texas at DallascoreStrategic or Co-development PartnerAcademic research partnership with UT Dallas, where the company was co-founded. Lakshman Tamil serves as Co-founder and Professor at UT Dallas. The partnership supports ongoing AI research and development for medical imaging.
  • University of Texas Southwestern Medical CentercoreStrategic or Co-development PartnerResearch collaboration with UTSW for AI development and validation in medical imaging. Part of Dallas-based healthcare ecosystem.
  • AWS Partner NetworkcoreTechnology or IntegrationMedCognetics is a member of the AWS Partner Network, enabling cloud-based deployment of FDA-cleared AI solutions through secure, HIPAA-compliant AWS infrastructure.
  • NM Medical, Mumbai, IndiacoreImplementation/ SI/ Consulting PartnerClinical deployment partnership with NM Medical in Mumbai, India. Dr. Shilpa Lad serves as radiologist advisor. Has screened thousands of patients across diverse ethnic demographics.
  • AKARUI SolutionscoreChannel Partner/ Reseller/ DistributorPartnership with AKARUI Solutions to deploy MedCognetics' AI imaging platform for expanding breast cancer screening access in rural India.
  • Four Nigerian University HospitalscoreImplementation/ SI/ Consulting PartnerDeployment of unbiased AI platform in four Nigerian university hospitals, screening thousands of patients across diverse ethnic demographics as part of the company's global health initiative.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Medcognetics competitors and assessment

Company assessment

Broad incumbents

  • Aidoc: Broad radiology AI platform with FDA-cleared algorithms across multiple modalities including chest CT, sold to large hospital systems—an incumbent MedCognetics competes against when extending into lung.
  • Hologic: Mammography equipment OEM (Selenia Dimensions / 3Dimensions) that bundles its own Genius AI for DBT. Competes both at the device level and the AI-software layer MedCognetics targets.

Direct peers

  • Riverain Technologies (ClearRead): Provides ClearRead CT and ClearRead XR AI tools for chest imaging, directly comparable to MedCognetics' CogNet Lung suite for lung cancer screening and chest X-ray analysis.
  • CureMetrix: Developer of cmTriage and cmAngio AI for mammography workflow and cancer detection, focused on the same hospital and imaging-center customer segment.
  • Therapixel: French AI vendor with MammoScreen 2.0 for mammography triage and detection, an FDA-cleared competitor to MedCognetics' CogNet AI-MT+ in the U.S. market.
  • Lunit: Korean AI company with INSIGHT MMG and INSIGHT DBT for mammography triage and detection, plus INSIGHT CXR for chest X-ray—directly overlapping MedCognetics' breast and lung AI roadmap and global commercial footprint.
  • iCAD, Inc. Mammography AI vendor behind ProFound AI for DBT and 2D mammography, with FDA-cleared triage, detection, and risk products serving U.S. hospitals and imaging centers in the same customer base.
  • Volpara Health Technologies: Provides AI-powered breast imaging analytics including density assessment and risk scoring (Volpara Scorecard), sold to the same hospital and imaging-center customers MedCognetics targets.
  • ScreenPoint Medical: Developer of Transpara, an FDA-cleared AI decision-support tool for mammography (2D and DBT) used in U.S. and European screening programs—directly comparable to CogNet AI-MT/AI-MT+.
  • DeepHealth (RadNet): RadNet-owned AI subsidiary offering Saige-Dx for mammography decision support and a broader radiology AI portfolio, with deep U.S. imaging-center distribution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Medcognetics social profiles

Digital presence

Medcognetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medcognetics leadership team

Management profile

Number of profiles

Profiles7 records

Medcognetics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medcognetics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medcognetics

What does Medcognetics do?

MedCognetics develops and licenses AI-powered medical imaging software for breast cancer and lung disease detection. Its core CogNet platform provides FDA-cleared computer-aided triage, detection, density classification, patient risk scoring, and breast arterial calcification analysis for mammography, as well as chest X-ray and low-dose CT analysis for lung screening. The software is offered via cloud, on-premises, embedded, and web portal deployment to hospitals, imaging centers, and global health programs.

Is Medcognetics a public or private company?

Medcognetics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Medcognetics founded?

Medcognetics was founded in 2020. It employs 1 to 10 people.

Where is Medcognetics based?

Medcognetics is headquartered in Dallas, United States, in the North America region.

How does Medcognetics make money?

One revenue line is on record: AI Software Licenses/Subscriptions.

Who are Medcognetics's main competitors?

Broad incumbents on record are Aidoc and Hologic. Direct peers are Riverain Technologies (ClearRead), CureMetrix, Therapixel, Lunit, iCAD, Inc., Volpara Health Technologies, ScreenPoint Medical and DeepHealth (RadNet).

Does Medcognetics have an API?

No public API is recorded for Medcognetics.

What industry is Medcognetics in?

Medcognetics's product category is Medical Imaging AI Software. Its primary akta.pro industry code is HLACALAC, Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories, with a secondary code of HLAHABAF, Mammography & Breast Imaging Systems. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewMedCognetics, Inc. AI Selected Across Texas Imaging CentersMedCognetics, Inc. selected its AI technology to support breast imaging across Innovative Health & Wellness's Texas outpatient imaging centers. The release provides no financial terms or quantified business impact. The next catalyst would be reported implementation scale or measurable revenue contribution.Digital Health NewsMedCognetics Partners with HWRF to Deploy AI-Enabled Mobile Mammography Units in IndiaMedCognetics, a Dallas-based medical imaging AI company and member of the AWS Partner Network, has partnered with the Health Within Reach Foundation (HWRF), a Pune-based nonprofit, to deploy AI-enabled mobile mammography units across India. The initiative aims to enhance early detection of breast cancer in underserved and remote rural regions by bringing screening devices directly to communities that would otherwise face significant barriers to care. The mobile units use an edge-based deployment model that enables real-time image processing and decision support in areas with limited or unreliable connectivity.BioSpaceMedCognetics and AWS Bring AI-Powered Breast Cancer Screening to Underserved Communities in IndiaMedCognetics and AWS announced a collaboration with Health Within Reach Foundation to deploy AI-enabled mobile mammography units in India for underserved populations. The partnership aims to bring breast cancer screening services directly to underprivileged communities. MedCognetics' AI platform integrates into radiology workflow and is trained on a diverse global dataset.NewsfileMedCognetics Receives FDA 510(k) Clearance for CogNet AI-MT+ Radiological Computer-Aided Triage and Notification SoftwareMedCognetics, Inc. announced on February 5, 2026 that it received U.S. Food and Drug Administration 510(k) clearance for CogNet AI-MT+, an AI-enabled radiological computer-aided triage and notification software designed for breast imaging. The software integrates into existing imaging systems to help radiologists manage increasing imaging volumes by flagging suspicious 3D mammography (DBT) exams for prioritized review. This clearance permits commercialization of the device in the United States under FDA Class II regulations.IndianpharmapostMedCognetics and Laurel Bridge unite to revolutionize breast cancer screening with secure AI workflowMedCognetics and Laurel Bridge Software have announced a strategic collaboration to integrate MedCognetics' AI breast cancer screening technology with Laurel Bridge's Compass workflow management platform. The partnership aims to enhance clinical efficiency, ensure robust data security through automated metadata de-identification, and facilitate seamless integration into existing radiology infrastructures. This alliance supports MedCognetics' mobile imaging initiatives and aligns with FDA guidelines for trustworthy AI in medical diagnostics.PharmiWeb.comMedCognetics Collaborates With Laurel Bridge Software to Revolutionize Breast Cancer Screening and Diagnosis With Secure, Advanced AI Workflow SolutionsMedCognetics, an AI company specializing in breast cancer screening, has partnered with Laurel Bridge Software to deliver an integrated solution for screening and diagnostic mammography that combines AI accuracy with secure workflow management. The collaboration, announced during Breast Cancer Awareness Month, addresses the FDA's requirements for AI in healthcare by meeting what the companies call the "trifecta" of trustworthy AI: clinical accuracy, workflow integration, and data security. Laurel Bridge's Compass Routing Workflow Manager provided the framework that helped MedCognetics obtain 510(k) clearance from the FDA.Pulse 2.0MedCognetics Reveals First Embedded AI Cancer Detection System For Mammography ImagingMedCognetics announced the successful testing and implementation of the first embedded AI cancer detection system for mammography, developed in collaboration with clinical leaders worldwide. The system utilizes the NVIDIA IGX Orin edge AI platform to process images directly within the mammography device, eliminating latency and providing immediate, high-quality analysis without requiring external workstations or cloud processing. This integration aims to improve patient outcomes through faster results and reduced hardware costs while offering easier software-based upgrades and maintenance for medical imaging centers.Pulse 2.0MedCognetics: Interview With President & CEO Ron Nag About This AI-Based Radiology Workflow CompanyMedCognetics, an AI software company specializing in breast cancer triage, detection, and risk prediction, has achieved key milestones including FDA clearance, a $750,000 NIH grant in January 2023, and a USPTO patent in March 2024. The company has deployed its unbiased AI platform in four Nigerian university hospitals and at NM Medical in Mumbai, India, screening thousands of patients across diverse ethnic demographics. CEO Debasish 'Ron' Nag outlined future goals including strategic partnerships, expanded deployments, and extending the technology beyond breast cancer detection.Medical BuyerMedCognetics awarded $750K grant from NIHMedCognetics has been awarded a $750,000 grant from the National Institutes of Health's AIM-AHEAD program to support its AI-based imaging algorithm for early cancer detection. The funding, structured as a subaward from the University of North Texas Health Science Center, aims to address health inequities by reducing data bias in medical imaging for historically ignored populations.Business Wire BlogMedCognetics Awarded $750,000 Grant from NIH to Research Unbiased Artificial Intelligence for Breast Cancer DetectionMedCognetics has been awarded a $750,000 grant from the National Institutes of Health's AIM-AHEAD program to research unbiased artificial intelligence algorithms for breast cancer detection. The funding is provided as a subaward through the University of North Texas Health Science Center to support the development of technology aimed at addressing data bias in medical imaging.